NDAINHALATIONAEROSOL, METERED
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DULERA is a fixed-dose combination inhaled corticosteroid (mometasone furoate) and long-acting beta-2 agonist (formoterol fumarate) approved for asthma maintenance therapy. It combines anti-inflammatory and bronchodilator mechanisms to reduce airway inflammation and improve airflow in patients with persistent asthma. The product targets patients requiring combination therapy to achieve asthma control.
$0.117BPart D
LOE ApproachingProduct approaching loss of exclusivity with $117M in Part D spending signals declining team investment and potential workforce restructuring in commercial roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Started Mar 2014
50 enrolled
Asthma
Why This Matters for Your Career
$117M Medicare spend — this is a commercially significant brand
Worked on DULERA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.